LDLR and neoplasm: This tumor‐activable nanoparticle hitchhikes on low‐density lipoproteins, concentrates in tumors via LDL receptor‐mediated endocytosis, and selectively releases oxaliplatin and SN38 in lysosome, resulting superior antitumor effects.